Nichi-Iko buys into Korean biosimilar capacity
This article was originally published in Scrip
Executive Summary
Nichi-Iko Pharmaceutical, one of Japan's largest generics firms, has acquired a 12.6% equity stake in Binex, a South Korean contract manufacturer, in an alliance it says will focus on the production of biosimilars.